Oct 2026· Cell Reports· Vol 45 11, pp.
118180
· 0 citations· 74 references
Medicine
TL;DR
Cryo-electron microscopy analysis revealed that 3CF5 targets a conserved non-receptor-binding epitope on the hemagglutinin (HA) head, spanning the vestigial esterase domain and an adjacent lateral surface, which mediates neutralization primarily through inhibiting membrane fusion and also possesses antibody-dependent cellular cytotoxicity.
Abstract
Avian influenza viruses of the H5Nx subtype pose persistent pandemic threats. Here, we immunized rhesus macaques with an H5N6 vaccine and obtained 30 H5-reactive monoclonal antibodies (mAbs). Three IgG mAbs, 3CF5, 3BG3, and 3BE7, demonstrated potent neutralizing activity against multiple H5Nx viruses and conferred protection in a lethal mouse challenge model. Notably, 3CF5 exhibited broad neutralization against H5Nx viruses spanning 1997-2024, including contemporary clade 2.3.4.4b H5N1 strains associated with an ongoing outbreak in dairy cattle. Cryo-electron microscopy (cryo-EM) analysis revealed that 3CF5 targets a conserved non-receptor-binding epitope on the hemagglutinin (HA) head, spanning the vestigial esterase domain and an adjacent lateral surface. 3CF5 mediates neutralization primarily through inhibiting membrane fusion and also possesses antibody-dependent cellular cytotoxicity. Furthermore, isotype conversion of 3CF5-IgG to mucosal secretory IgA1 (sIgA1) enhanced neutralization potency against H5N1 viruses up to 128-fold, highlighting the advantage of sIgA1 as a nasally administered prophylactic agent.
The structural basis for C12A6-mediated cross-neutralization is defined and the functional architecture of gB DI is illuminated as a target for broad-spectrum antiviral development.
Yu Li, Cheng-Yu Yang, G. Wang et al.· Cell Reports· 0 citations
Influenza A virus continues to pose pandemic threats, as demonstrated by the recent global spread of highly pathogenic H5N1 strains. Consequently, the development and characterization of vaccines targeting zoonotic influenza subtypes have become a major focus of the field. In this study, we characterize two broadly rea...
Guthrie L. Stroh, Hui-Bin Lv, Chun-Ke Chen et al.· bioRxiv· 0 citations
Second-generation VXA-H5–02 is a promising vaccine candidate capable of inducing systemic and mucosal immunity, offering broad protection against HPAI, and significantly reduced illness, viral burden, and shedding.
Becca A. Flitter, Ka-Yan Tam, Laura J. Showalter et al.· Frontiers in Immunology· 0 citations
This multi-epitope DNA vaccine elicited cross-protective immunity against influenza A/H1N1 and A/H3N2 by targeting conserved HA and PA epitopes, supporting its potential as a candidate for universal influenza vaccine development.
K. Barkhordari, F. Rezaei, V. Salimi et al.· Iranian Journal of Microbiol...· 0 citations
ABSTRACT Influenza A virus (IAV) zoonotic transmission and continuous evolution in multiple host species heighten the risk of emerging novel strains at the human-animal interface. Digitally immune-optimized hemagglutinin (HA), neuraminidase (NA), and matrix-2 (M2) vaccine antigens were engineered and combined as a sing...
J. D. Del Rosario, P. V. van Diemen, Simon D. W. Frost et al.· Journal of Virology· 0 citations
The continuing evolution of monkeypox virus (MPXV) clades capable of sustained human-to-human transmission poses an escalating global health risk, yet no effective therapy exists for poxvirus infection. Here, we investigate a panel of human monoclonal antibodies (mAbs), derived from an antibody library, which targets A...
Ding Zhang, R. Fantin, Xue-Yong Zhu et al.· Science immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.